Drugs / ST2210
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02053324 | Nov 2013 → Jun 2019 | metastasis from malignant tumor of colon | Alfasigma S.p.A. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ST2210 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02053324 ↗ |
| Known as | (177)Lu-ST2210 | “AvidinOX-pretargeted (177)Lu-biotinDOTA ((177)Lu-ST2210) is currently under clinical investigation for the treatment of liver oligometastases from colorectal cancer...” PMID 26167947 ↗ Jul 2015 |
| Route | Intravenous | “intravenous infusion of ST2210” NCT02053324 ↗ |